A New Tool for Oral Solubility Enhancement: Discover the Potential of Apinovex™ Polymers
In this webinar, Lubrizol and their partner, RCPE, will present several new case studies that demonstrate the solubility-enhancing properties of the Apinovex™ polymer technology. Promising safety/toxicity study outcomes for the polymer will also be presented.
As poor solubility and bioavailability become more prevalent in the drug pipeline, new formulation tools are needed to develop viable, effective drug products.
In 2022, Lubrizol launched its Apinovex™ polymers, which offer formulation scientists high drug loading capacity and powerful solubilizing properties for oral solid dosage forms. With Apinovex™ polymers, scientists can rescue challenging NCEs from the development graveyard or unlock lucrative 505(b)(2) product development opportunities.
In this webinar, Lubrizol and their partner, RCPE, will present several new case studies that demonstrate the solubility-enhancing properties of the Apinovex™ polymer technology. Promising safety/toxicity study outcomes for the polymer will also be presented.
Key Takeaways:
- Overview and introduction to the Apinovex™ polymer technology
- Solubility enhancement data across a range of APIs with varying physicochemical properties
- Case study data comparing Apinovex™ polymers to traditional solubility-enhancing excipients
- Safety and toxicity studies, including in vivo test results
